Supriya Lifescience — 360° view

Supriya Lifescience, a company in the Pharmaceuticals industry, reported revenue of ₹206 crore and net profit of ₹29 crore for the September 2026 quarter.

Supriya Lifescience (NSE: SUPRIYA) closed at ₹620.15 on 20 Nov 2026, down 19.8% over the past year. Its market capitalisation is ₹4,991 crore and it trades at 28.1 times earnings.

Share price
₹620.15 (20 Nov 2026)
Market cap
₹4,991 Cr (20 Nov 2026)
P/E
28.11 (20 Nov 2026)
Revenue
₹206 Cr (September 2026 quarter)
Net profit
₹29 Cr (September 2026 quarter)
ROCE
25.2% (FY26)
ROE
19.1% (FY26)
Book value
₹154 (FY26)
Dividend yield
0.16% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,085.00 / ₹545.50 (20 Nov 2026)
1-year return
-19.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SUPRIYA

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.